Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Core Points - Genprex, Inc. has announced a registered direct offering of 243,622 shares of common stock at a price of $11.21 per share, with expected gross proceeds of approximately $2.7 million [1][2] - The company will also issue unregistered short-term warrants to purchase up to 487,244 shares at an exercise price of $11.00 per share, potentially adding up to $5.4 million in gross proceeds if fully exercised [1][2] - The offering is expected to close around October 24, 2025, pending customary closing conditions [1] Financial Details - The gross proceeds from the offering are estimated at $2.7 million before deducting fees and expenses [2] - If the short-term warrants are fully exercised, the additional gross proceeds could reach approximately $5.4 million [2] Regulatory Information - The shares are being offered under a "shelf" registration statement declared effective by the SEC on June 9, 2023 [3] - The unregistered warrants and underlying shares are offered in a private placement and have not been registered under the Securities Act [4] Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes [6] - The company's lead product candidate, Reqorsa® Gene Therapy, is in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [7] - Genprex's diabetes gene therapy approach aims to transform pancreatic alpha cells into functional beta-like cells to produce insulin [7]